Form 4: iTeos Therapeutics CEO Michel Detheux Receives Stock Options and Restricted Stock Units

Michel Detheux, CEO of iTeos Therapeutics, was granted stock options and restricted stock units (RSUs) on March 7, 2025, according to a Form 4 filing with the SEC.

Summary

• Michel Detheux, the CEO of iTeos Therapeutics, received 77,000 restricted stock units (RSUs) and options to purchase 459,000 shares of common stock on March 7, 2025.
• The RSUs vest over four years, with 25% vesting on March 7, 2026, and the remainder vesting equally on an annual basis over the subsequent three years, contingent upon continued service.
• The stock options, with an exercise price of $7.05, also vest over four years, with 25% vesting on March 7, 2026, and the rest vesting in equal monthly installments over the following 36 months, subject to continued service.
• Following these transactions, Detheux directly owns 135,903 shares of common stock and options to purchase 459,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity aligns management with shareholder interests, which is generally viewed favorably. However, it also represents potential dilution for existing shareholders.

Positives

• The grant of RSUs and stock options aligns the CEO's interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedules encourage long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Grants of stock options and RSUs are common practices in the biotechnology industry to attract and retain top executive talent and align their interests with those of shareholders. The vesting schedules are designed to incentivize long-term performance and commitment.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for CEOs in the biotech industry.
• Vesting schedules of four years with a one-year cliff (25% vesting after one year) are also typical.
• Comparing the size of the grant to similar companies (e.g., Arcus Biosciences, Gritstone Bio) would provide further context on whether the grant is above or below industry averages.

Stakeholder Impact

• Shareholders may experience dilution if the stock options are exercised.
• Employees may be motivated by the CEO's increased alignment with company performance.

Key Dates